Trial of Anifrolumab in Active Systemic Lupus Erythematosus
A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite primary end point of lupus scores. A previous phase 3 trial failed to meet its primary objective but showed an effect in secondary end points.
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2020-01, Vol.382 (3), p.211-221 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 221 |
|---|---|
| container_issue | 3 |
| container_start_page | 211 |
| container_title | The New England journal of medicine |
| container_volume | 382 |
| creator | Morand, Eric F Furie, Richard Tanaka, Yoshiya Bruce, Ian N Askanase, Anca D Richez, Christophe Bae, Sang-Cheol Brohawn, Philip Z Pineda, Lilia Berglind, Anna Tummala, Raj |
| description | A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite primary end point of lupus scores. A previous phase 3 trial failed to meet its primary objective but showed an effect in secondary end points. |
| doi_str_mv | 10.1056/NEJMoa1912196 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2339137768</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2339137768</sourcerecordid><originalsourceid>FETCH-LOGICAL-c544t-8eaf02c6ae8f57fc2e0f94e489de5cfc24dc508bc759690c70e4278a233024b03</originalsourceid><addsrcrecordid>eNp10EtLAzEUBeAgiq3VpVsZEJejeU4SXJVSX1RdWNchkyY4pZmpyaTQf2-kVXDh3VwufJwLB4BzBK8RZNXNy_TpudNIIoxkdQCGiBFSUgqrQzCEEIuSckkG4CTGJcyDqDwGA4IEQ1yyIbidh0avis4V47ZxoVslr-uiaYux6ZuNLd62sbe-McUsrVMspmHbf1iv-y6meAqOnF5Fe7bfI_B-N51PHsrZ6_3jZDwrDaO0L4XVDmJTaSsc485gC52klgq5sMzkmy4Mg6I2nMlKQsOhpZgLjQmBmNaQjMDlLncdus9kY6-WXQptfqmykYhwXomsyp0yoYsxWKfWofE6bBWC6rsq9aeq7C_2qan2dvGrf7rJ4GoHvI-qtUv_T9AXcYduog</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2339137768</pqid></control><display><type>article</type><title>Trial of Anifrolumab in Active Systemic Lupus Erythematosus</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Morand, Eric F ; Furie, Richard ; Tanaka, Yoshiya ; Bruce, Ian N ; Askanase, Anca D ; Richez, Christophe ; Bae, Sang-Cheol ; Brohawn, Philip Z ; Pineda, Lilia ; Berglind, Anna ; Tummala, Raj</creator><creatorcontrib>Morand, Eric F ; Furie, Richard ; Tanaka, Yoshiya ; Bruce, Ian N ; Askanase, Anca D ; Richez, Christophe ; Bae, Sang-Cheol ; Brohawn, Philip Z ; Pineda, Lilia ; Berglind, Anna ; Tummala, Raj ; TULIP-2 Trial Investigators</creatorcontrib><description>A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite primary end point of lupus scores. A previous phase 3 trial failed to meet its primary objective but showed an effect in secondary end points.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1912196</identifier><identifier>PMID: 31851795</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Adult ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Bronchitis ; Double-Blind Method ; Female ; Glucocorticoids ; Glucocorticoids - therapeutic use ; Herpes zoster ; Humans ; Immunoglobulins ; Immunosuppressive agents ; Infusions, Intravenous ; Interferon ; Intravenous administration ; Laboratories ; Lupus ; Lupus Erythematosus, Systemic - drug therapy ; Male ; Middle Aged ; Monoclonal antibodies ; Receptor, Interferon alpha-beta - antagonists & inhibitors ; Severity of Illness Index ; Skin diseases ; Statistical analysis ; Systemic lupus erythematosus</subject><ispartof>The New England journal of medicine, 2020-01, Vol.382 (3), p.211-221</ispartof><rights>Copyright © 2019 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2019 Massachusetts Medical Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c544t-8eaf02c6ae8f57fc2e0f94e489de5cfc24dc508bc759690c70e4278a233024b03</citedby><cites>FETCH-LOGICAL-c544t-8eaf02c6ae8f57fc2e0f94e489de5cfc24dc508bc759690c70e4278a233024b03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1912196$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa1912196$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31851795$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morand, Eric F</creatorcontrib><creatorcontrib>Furie, Richard</creatorcontrib><creatorcontrib>Tanaka, Yoshiya</creatorcontrib><creatorcontrib>Bruce, Ian N</creatorcontrib><creatorcontrib>Askanase, Anca D</creatorcontrib><creatorcontrib>Richez, Christophe</creatorcontrib><creatorcontrib>Bae, Sang-Cheol</creatorcontrib><creatorcontrib>Brohawn, Philip Z</creatorcontrib><creatorcontrib>Pineda, Lilia</creatorcontrib><creatorcontrib>Berglind, Anna</creatorcontrib><creatorcontrib>Tummala, Raj</creatorcontrib><creatorcontrib>TULIP-2 Trial Investigators</creatorcontrib><title>Trial of Anifrolumab in Active Systemic Lupus Erythematosus</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite primary end point of lupus scores. A previous phase 3 trial failed to meet its primary objective but showed an effect in secondary end points.</description><subject>Adult</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Bronchitis</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Glucocorticoids</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Herpes zoster</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Immunosuppressive agents</subject><subject>Infusions, Intravenous</subject><subject>Interferon</subject><subject>Intravenous administration</subject><subject>Laboratories</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Receptor, Interferon alpha-beta - antagonists & inhibitors</subject><subject>Severity of Illness Index</subject><subject>Skin diseases</subject><subject>Statistical analysis</subject><subject>Systemic lupus erythematosus</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10EtLAzEUBeAgiq3VpVsZEJejeU4SXJVSX1RdWNchkyY4pZmpyaTQf2-kVXDh3VwufJwLB4BzBK8RZNXNy_TpudNIIoxkdQCGiBFSUgqrQzCEEIuSckkG4CTGJcyDqDwGA4IEQ1yyIbidh0avis4V47ZxoVslr-uiaYux6ZuNLd62sbe-McUsrVMspmHbf1iv-y6meAqOnF5Fe7bfI_B-N51PHsrZ6_3jZDwrDaO0L4XVDmJTaSsc485gC52klgq5sMzkmy4Mg6I2nMlKQsOhpZgLjQmBmNaQjMDlLncdus9kY6-WXQptfqmykYhwXomsyp0yoYsxWKfWofE6bBWC6rsq9aeq7C_2qan2dvGrf7rJ4GoHvI-qtUv_T9AXcYduog</recordid><startdate>20200116</startdate><enddate>20200116</enddate><creator>Morand, Eric F</creator><creator>Furie, Richard</creator><creator>Tanaka, Yoshiya</creator><creator>Bruce, Ian N</creator><creator>Askanase, Anca D</creator><creator>Richez, Christophe</creator><creator>Bae, Sang-Cheol</creator><creator>Brohawn, Philip Z</creator><creator>Pineda, Lilia</creator><creator>Berglind, Anna</creator><creator>Tummala, Raj</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20200116</creationdate><title>Trial of Anifrolumab in Active Systemic Lupus Erythematosus</title><author>Morand, Eric F ; Furie, Richard ; Tanaka, Yoshiya ; Bruce, Ian N ; Askanase, Anca D ; Richez, Christophe ; Bae, Sang-Cheol ; Brohawn, Philip Z ; Pineda, Lilia ; Berglind, Anna ; Tummala, Raj</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c544t-8eaf02c6ae8f57fc2e0f94e489de5cfc24dc508bc759690c70e4278a233024b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Bronchitis</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Glucocorticoids</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Herpes zoster</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Immunosuppressive agents</topic><topic>Infusions, Intravenous</topic><topic>Interferon</topic><topic>Intravenous administration</topic><topic>Laboratories</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Receptor, Interferon alpha-beta - antagonists & inhibitors</topic><topic>Severity of Illness Index</topic><topic>Skin diseases</topic><topic>Statistical analysis</topic><topic>Systemic lupus erythematosus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morand, Eric F</creatorcontrib><creatorcontrib>Furie, Richard</creatorcontrib><creatorcontrib>Tanaka, Yoshiya</creatorcontrib><creatorcontrib>Bruce, Ian N</creatorcontrib><creatorcontrib>Askanase, Anca D</creatorcontrib><creatorcontrib>Richez, Christophe</creatorcontrib><creatorcontrib>Bae, Sang-Cheol</creatorcontrib><creatorcontrib>Brohawn, Philip Z</creatorcontrib><creatorcontrib>Pineda, Lilia</creatorcontrib><creatorcontrib>Berglind, Anna</creatorcontrib><creatorcontrib>Tummala, Raj</creatorcontrib><creatorcontrib>TULIP-2 Trial Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morand, Eric F</au><au>Furie, Richard</au><au>Tanaka, Yoshiya</au><au>Bruce, Ian N</au><au>Askanase, Anca D</au><au>Richez, Christophe</au><au>Bae, Sang-Cheol</au><au>Brohawn, Philip Z</au><au>Pineda, Lilia</au><au>Berglind, Anna</au><au>Tummala, Raj</au><aucorp>TULIP-2 Trial Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trial of Anifrolumab in Active Systemic Lupus Erythematosus</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2020-01-16</date><risdate>2020</risdate><volume>382</volume><issue>3</issue><spage>211</spage><epage>221</epage><pages>211-221</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite primary end point of lupus scores. A previous phase 3 trial failed to meet its primary objective but showed an effect in secondary end points.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>31851795</pmid><doi>10.1056/NEJMoa1912196</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2020-01, Vol.382 (3), p.211-221 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_2339137768 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Adult Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Bronchitis Double-Blind Method Female Glucocorticoids Glucocorticoids - therapeutic use Herpes zoster Humans Immunoglobulins Immunosuppressive agents Infusions, Intravenous Interferon Intravenous administration Laboratories Lupus Lupus Erythematosus, Systemic - drug therapy Male Middle Aged Monoclonal antibodies Receptor, Interferon alpha-beta - antagonists & inhibitors Severity of Illness Index Skin diseases Statistical analysis Systemic lupus erythematosus |
| title | Trial of Anifrolumab in Active Systemic Lupus Erythematosus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T15%3A45%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trial%20of%20Anifrolumab%20in%20Active%20Systemic%20Lupus%20Erythematosus&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Morand,%20Eric%20F&rft.aucorp=TULIP-2%20Trial%20Investigators&rft.date=2020-01-16&rft.volume=382&rft.issue=3&rft.spage=211&rft.epage=221&rft.pages=211-221&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa1912196&rft_dat=%3Cproquest_cross%3E2339137768%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2339137768&rft_id=info:pmid/31851795&rfr_iscdi=true |